Characteristics and conflicting recommendations of clinical practice guidelines for COVID-19 management in children: A scoping review

Quincho-Lopez, Alvaro; Chávez-Rimache, Lesly; Montes-Alvis, José; Taype-Rondán, Álvaro; Alvarado-Gamarra, Giancarlo

doi:10.1016/j.tmaid.2022.102354

Cited by 5 publications

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…La administración de inmunoglobulinas se encontró dentro de lo habitual para pacientes con PIMS, debido a evidencia indirecta de posible beneficio de otras patologías, tales como enfermedad de Kawasaki, síndrome de activación mastocitaria, entre otras (17) . En nuestro estudio, 68,2% de los niños con PIMS recibieron inmunoglobulinas.…”

Section: Discussionunclassified

Uso de medicamentos en pacientes pediátricos con COVID-19 hospitalizados en un hospital de referencia de Lima, Perú

Luna-Vilchez

Mejia

Ortiz-Benique

et al. 2023

Rev Peru Med Exp Salud Publica

View full text Add to dashboard Cite

El objetivo del estudio fue describir el uso de medicamentos en pacientes pediátricos con COVID-19 hospitalizados en el Instituto Nacional de Salud del Niño – San Borja (INSN-SB) de Lima, Perú, entre marzo del 2020 y marzo del 2022. Por ello, realizamos un estudio observacional descriptivo y evaluamos el uso de seis medicamentos: corticoides, ceftriaxona, azitromicina, inmunoglobulina, hidroxicloroquina e ivermectina. Finalmente, comparamos los resultados entre subpoblaciones definidas según la ola de la pandemia por COVID-19. Incluimos 421 pacientes pediátricos. Al 40,4% se le indicó corticoides, 35,6%ceftriaxona, 12,1% azitromicina, 3,6% inmunoglobulina, 2,4% hidroxicloroquina y 0,5% ivermectina. El uso de ceftriaxona y azitromicina fue menos frecuente durante la tercera ola. El uso de hidroxicloroquina fue casi exclusivo de la primera ola. El uso de inmunoglobulina solo se observó en pacientes con síndrome inflamatorio multisistémico pediátrico. La indicación de los medicamentos evaluados fue en generalmenor en la tercera ola.

show abstract

Section: Discussionunclassified

Uso de medicamentos en pacientes pediátricos con COVID-19 hospitalizados en un hospital de referencia de Lima, Perú

Luna-Vilchez

Mejia

Ortiz-Benique

et al. 2023

Rev Peru Med Exp Salud Publica

View full text Add to dashboard Cite

show abstract

Exploring the concordance of recommendations across guidelines on chest imaging for the diagnosis and management of COVID-19: A proposed methodological approach based on a case study

Yaacoub¹,

Chamseddine²,

Jaber³

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

Objective To describe a methodological approach to explore the concordance of recommendations across guidelines and its application to the case of the WHO recommendations on chest imaging for the diagnosis and management of COVID-19. Study design and setting We followed a methodological approach applied to a case study that included: defining the ‘reference guideline’ (i.e., the WHO guidance) and the ‘reference recommendations’; searching for ‘related guidelines’ and identifying ‘related recommendations’; constructing the PICO for the recommendations; assessing the matching of the PICO of each related recommendation to the PICO corresponding reference recommendation; and assessing the concordance between the PICO-matching recommendations. Results We identified a total of 89 related recommendations from 22 related guidelines. Out of the 89 related recommendations, 43 partly matched and 1 entirely matched one of the reference recommendations, and out of these, 8 were concordant with one of the reference recommendations. When considering the seven reference recommendations, they had a median of 12 related recommendations (range 3–17), a median of 7 PICO-matching recommendations (range 0–13), and a median of 1 concordant recommendation (range 0–4). Conclusion Following a detailed methodological approach, we were able to explore the concordance between our reference recommendations and related recommendations from other guidelines. A relatively low percentage of recommendations was concordant.

show abstract

Remdesivir: the first FDA-approved anti-COVID-19 Treatment for Young Children

Chera

Tanca

2022

Discoveries

View full text Add to dashboard Cite

Following the emergence of the SARS-CoV-2 pandemic, finding efficient forms of treatment is seen as a priority for both adults and children. On April 25, 2022, remdesivir has become the first United States Food and Drug Administration (FDA) approved COVID-19 treatment for young children, specifically ≥28-days-old children, weighing ≥3 kilograms, who are either hospitalized or nonhospitalized, showing a high risk for progression to severe COVID-19 (prone to hospitalization or death). This new approval, which expands its already FDA-approved use in adults to young children, is supported by the CARAVAN study (a phase 2/3 single-arm, open-label study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of remdesivir (GS-5734™) in participants, from birth to < 18 years of age, with COVID-19). This study is in progress, with an estimated primary completion in February 2023. While positive effects of remdesivir have been ascertained through various studies, controversy has surrounded remdesivir since its initial FDA approval in 2020 due to the contradictory results obtained by various studies. However, many case reports state its positive effects on the outcome of the patients, encouraging an optimistic vision for the future.

show abstract

Characteristics and conflicting recommendations of clinical practice guidelines for COVID-19 management in children: A scoping review

Cited by 5 publications

References 34 publications

Uso de medicamentos en pacientes pediátricos con COVID-19 hospitalizados en un hospital de referencia de Lima, Perú

Uso de medicamentos en pacientes pediátricos con COVID-19 hospitalizados en un hospital de referencia de Lima, Perú

Exploring the concordance of recommendations across guidelines on chest imaging for the diagnosis and management of COVID-19: A proposed methodological approach based on a case study

Remdesivir: the first FDA-approved anti-COVID-19 Treatment for Young Children

Contact Info

Product

Resources

About